- Psilocybin trials showed smaller symptom reduction compared to SSRIs and esketamine.
- Meta-analysis involved 17 clinical trials on adults with MDD or TRD.
- MADRS was used for assessing depressive symptom severity.
- Active treatment response rates were 48% for psilocybin.
- Lower response rates may reflect functional unblinding in psilocybin trials.
- Future studies should evaluate multiple control treatment types.
- Rigor in trial design is essential for accurate treatment evaluation.
Source: JAMA Network Open
